Literature DB >> 20393724

[Driving competency after combined treatment with methylprednisolone and orbital radiotherapy for endocrine orbitopathy].

I Sterker1, H Tegetmeyer, K Papsdorf, D Führer.   

Abstract

OBJECTIVE: Graves' orbitopathy (GO) in its moderate to severe expression is a disfiguring and disabling disease that profoundly influences activities of daily living. Intravenous steroids and orbital radiotherapy are effective treatments for moderate to severe active GO. We examined the ophthalmological outcomes regarding daily life activities, such as driving competency.
MATERIALS AND METHODS: In a retrospective case series, we evaluated the data for 21 consecutive patients with moderate to severe and active GO (14 women and seven men) treated with combined orbital radiotherapy (13 Gy) and intravenous methylprednisolone (500 mg weekly for 6 consecutive weeks and 250 mg weekly for consecutive 6 weeks).
RESULTS: The pretreatment mean clinical activity score of 5.2 points (SD ± 0.9) decreased significantly to 2.7 points (SD ± 1.1) in the 12-month follow-up. Analysis of all ocular symptoms showed significant changes for four parameters with different time frames. Inflammatory eye signs--e.g., pain and pressure sensation, caruncle inflammation, and eyelid swelling, including exophthalmos--improved significantly within the first 3 months. Eyelid swelling was significantly reduced 6-12 months after therapy. However, there was no significant improvement of eye motility. Despite anti-inflammatory treatment, 11 patients (52.3%) were not fit to drive a car under binocular conditions. In eight of these patients, additional strabismologic therapy, including prisms or strabismus surgery, was successful.
CONCLUSION: The combined therapy of intravenous corticosteroids and orbital radiotherapy reduced inflammatory ophthalmological signs in different time frames. In most cases, strabismologic intervention, including eye muscle surgery, was necessary to restore driving competency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393724     DOI: 10.1007/s00347-010-2135-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  12 in total

1.  Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.

Authors:  M P Mourits; M L van Kempen-Harteveld; M B García; H P Koppeschaar; L Tick; C B Terwee
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

2.  Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease.

Authors:  M Weissel; W Hauff
Journal:  Thyroid       Date:  2000-06       Impact factor: 6.568

3.  Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy.

Authors:  Michele Marinó; Eugenia Morabito; Maurizia Rossana Brunetto; Luigi Bartalena; Aldo Pinchera; Claudio Marocci
Journal:  Thyroid       Date:  2004-05       Impact factor: 6.568

4.  Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

5.  Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.

Authors:  George J Kahaly; Susanne Pitz; Gerhard Hommel; Manuela Dittmar
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

Review 6.  Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.

Authors:  R S Bahn; C A Gorman
Journal:  Endocrinol Metab Clin North Am       Date:  1987-06       Impact factor: 4.741

Review 7.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

8.  Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.

Authors:  C Marcocci; L Bartalena; M L Tanda; L Manetti; E Dell'Unto; R Rocchi; G Barbesino; B Mazzi; M P Bartolomei; P Lepri; F Cartei; M Nardi; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

9.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

10.  A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Authors:  Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.